» Articles » PMID: 35947676

Differentiation of Crescent-forming Kidney Progenitor Cells into Podocytes Attenuates Severe Glomerulonephritis in Mice

Abstract

Crescentic glomerulonephritis is characterized by vascular necrosis and parietal epithelial cell hyperplasia in the space surrounding the glomerulus, resulting in the formation of crescents. Little is known about the molecular mechanisms driving this process. Inducing crescentic glomerulonephritis in two Pax2Cre reporter mouse models revealed that crescents derive from clonal expansion of single immature parietal epithelial cells. Preemptive and delayed histone deacetylase inhibition with panobinostat, a drug used to treat hematopoietic stem cell disorders, attenuated crescentic glomerulonephritis with recovery of kidney function in the two mouse models. Three-dimensional confocal microscopy and stimulated emission depletion superresolution imaging of mouse glomeruli showed that, in addition to exerting an anti-inflammatory and immunosuppressive effect, panobinostat induced differentiation of an immature hyperplastic parietal epithelial cell subset into podocytes, thereby restoring the glomerular filtration barrier. Single-cell RNA sequencing of human renal progenitor cells in vitro identified an immature stratifin-positive cell subset and revealed that expansion of this stratifin-expressing progenitor cell subset was associated with a poor outcome in human crescentic glomerulonephritis. Treatment of human parietal epithelial cells in vitro with panobinostat attenuated stratifin expression in renal progenitor cells, reduced their proliferation, and promoted their differentiation into podocytes. These results offer mechanistic insights into the formation of glomerular crescents and demonstrate that selective targeting of renal progenitor cells can attenuate crescent formation and the deterioration of kidney function in crescentic glomerulonephritis in mice.

Citing Articles

Effects of reduced extracellular sodium on proliferation and invasive activity of renal cell carcinoma cell lines.

Naldi L, Catalano M, Melica M, Polvani S, Papini D, Landini I Sci Rep. 2025; 15(1):8067.

PMID: 40055463 PMC: 11889168. DOI: 10.1038/s41598-025-92674-6.


Kidney immunology from pathophysiology to clinical translation.

Kurts C, von Vietinghoff S, Krebs C, Panzer U Nat Rev Immunol. 2025; .

PMID: 39885266 DOI: 10.1038/s41577-025-01131-y.


Pathogenesis of HIV-associated nephropathy in children and adolescents: taking a hard look 40 years later in the era of gene-environment interactions.

Ray P, Li J, Das J, Xu L, Yu J, Han Z Am J Physiol Renal Physiol. 2024; 327(6):F1049-F1066.

PMID: 39323389 PMC: 11687833. DOI: 10.1152/ajprenal.00208.2024.


How Stem and Progenitor Cells Can Affect Renal Diseases.

Montenegro F, Giannuzzi F, Picerno A, Cicirelli A, Stea E, Di Leo V Cells. 2024; 13(17.

PMID: 39273032 PMC: 11393889. DOI: 10.3390/cells13171460.


Uncovering the Role of Anoikis-Related Genes in Modulating Immune Infiltration and Pathogenesis of Diabetic Kidney Disease.

Lin J, Lin Y, Li X, He F, Gao Q, Wang Y J Inflamm Res. 2024; 17:4975-4991.

PMID: 39070131 PMC: 11283803. DOI: 10.2147/JIR.S446752.


References
1.
Bhatlekar S, Fields J, Boman B . Role of HOX Genes in Stem Cell Differentiation and Cancer. Stem Cells Int. 2018; 2018:3569493. PMC: 6081605. DOI: 10.1155/2018/3569493. View

2.
Park J, Shrestha R, Qiu C, Kondo A, Huang S, Werth M . Single-cell transcriptomics of the mouse kidney reveals potential cellular targets of kidney disease. Science. 2018; 360(6390):758-763. PMC: 6188645. DOI: 10.1126/science.aar2131. View

3.
Grabiec A, Korchynskyi O, Tak P, Reedquist K . Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay. Ann Rheum Dis. 2011; 71(3):424-31. PMC: 3277722. DOI: 10.1136/ard.2011.154211. View

4.
Chen A, Lee K, DAgati V, Wei C, Fu J, Guan T . Bowman's capsule provides a protective niche for podocytes from cytotoxic CD8+ T cells. J Clin Invest. 2018; 128(8):3413-3424. PMC: 6063505. DOI: 10.1172/JCI97879. View

5.
Evrot E, Ebel N, Romanet V, Roelli C, Andraos R, Qian Z . JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease. Clin Cancer Res. 2013; 19(22):6230-41. DOI: 10.1158/1078-0432.CCR-13-0905. View